Through genomic sequencing and analysis, clinicians can identify specific mutations present in a patient’s cancer cells and deliver personalized treatment based on the genetic information. Increased availability and lower costs of next-generation sequencing (NGS) and analysis, along with the on-going identification of an expanding array of cancer-related genetic mutations and biomarkers, are enabling exponential growth in the use of this diagnostic and therapy-targeting tool.
Multiple sequencing strategies, including whole genome, hybrid capture and amplicon sequencing are available, and there are also multiple options for the different steps of the workflow, such as fragmentation and size selection. Each technique has pros and cons, and selection will depend on your sample type, throughput requirements, targets, and other factors.
DNA sequence analysis techniques include read alignment, sequence alignment and variant calling. The accuracy of DNA sequence analysis starts from data generation, so your choices of strategies and methods in the sequencing workflow will affect your analysis.
Dr. Yaoyu will tie all this information together and illustrate it with a study example: Waldenstrom Macroglobulinemia.
In this webinar you will:
Learn about the application of next-generation sequencing (NGS) for cancer genomics analysis.
Understand DNA sequencing methods, with particular focus on fragmentation and size selection.
See how DNA sequence analysis is applied to identify somatic mutations that can serve as clinical biomarkers.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.